Dergiler / Electrica / 2018 / Cilt: 18 - Sayı: 2

Cloning of Presenilin 2 cDNA and Construction of Vectors Carrying Effective Mutations in the Pathogenesis of Familial Alzheimer's Disease

Sayfa
310–320
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

In future studies, it will be determined if there is an increase in Aβ42 protein levels, andthe effect on this early onset AD can be identified.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Alzheimer's disease (AD) is a neurodegenerative disease and is identified by the detection of amyloid-plaques and neurofibrillary tangles in the brain.Amyloid precursor protein gene, presenilin 1 (PSEN1) gene, and presenilin 2 (PSEN2) gene are responsible for this disease.
📊
Temel Bulgular & Veri:PSEN2 and amyloid precursorprotein (APP) gene mutations are a much rarer cause of familial AD patients.
💡
Sonuç & Katkı:In future studies, it will be determined if there is an increase in Aβ42 protein levels, andthe effect on this early onset AD can be identified.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Alzheimer's disease (AD) is a neurodegenerative disease and is identified by the detection of amyloid-plaques and neurofibrillary tangles in the brain.Amyloid precursor protein gene, presenilin 1 (PSEN1) gene, and presenilin 2 (PSEN2) gene are responsible for this disease. PSEN2 and amyloid precursorprotein (APP) gene mutations are a much rarer cause of familial AD patients. This study aims to clone the PSEN2 gene and create vectors with differentmutations by directed mutagenesis. As a result of the experiments, the PSEN2 cDNA was cloned between the BamHI and KpnI cut-off points of thepBluescript II sk (+) vector. PSEN1 and PSEN2 homologs have a role in cell destiny decision and AD progress. We studied some of the PSEN2 mutations(Ala252Thr and Pro334Arg) and provided expression analysis in eukaryotic cell cultures. Amyloid β-protein (Aβ), which is produced by endoproteolyticcleavage of the APP, is considered to play a role in AD. While nominal concentration of Aβ40 is 10 times of Aβ42, the last peptide is firmly linked to ADpathogenesis. Amyloid β-protein is generated by the γ-secretase cleavage of APP onset and the progression of AD, and it is the primary ingredient of thesenile plaques. The Aβ42 dodecamer plays a central role in AD. In future studies, it will be determined if there is an increase in Aβ42 protein levels, andthe effect on this early onset AD can be identified.

🔖

Bu Makaleye Atıf Yap

İŞSEVER, H., ÖZTAN, G., YOKEŞ, B. (2022). Cloning of Presenilin 2 cDNA and Construction of Vectors Carrying Effective Mutations in the Pathogenesis of Familial Alzheimer's Disease. Electrica, Cilt: 18 - Sayı: 2, 310–320. https://ajindex.com/articles/499919

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. A Kumar, S. A. Ekavali, “A review on Alzheimer’s disease pathophysiology and its management: an update”, Pharmacol Rep, vol. 67, no. 2, pp. 195-203, 2015.
  2. J. Guo, J. Cheng, B. J. North, W. Wei, “Functional analyses of major cancer-related signaling pathways in Alzheimer’s disease etiology”, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol. 1868, no. 2, pp. 341-358, 2017.
  3. P. A. Defina, R. S. Moser, M. Glenn, J. D. Lichtenstein, J Fellus, “Alzheimer’s Disease Clinical and Research Update for Health Care Practitioners”, J Aging Res, 2013.
  4. S. Parvathy, D. J. Buxbaum, “Molecular Genetics of Alzheimer Disease”, Neuropsychopharmacology: The Fifth Generation of Progress, pp. 1199-1213, 2002.
  5. L. Crews, E. Masliah, “Molecular mechanisms of neurodegeneration in Alzheimer’s disease”, Human Molecular Genetics, vol. 19, no. R1, pp. 12-20, 2010. M. B. Yokes, “Molecular genetics of Alzheimer’s Disease”, J Cell Mol Biol, vol. 6, no. 2, pp. 73-97, 2007.
  6. P. H. St George-Hyslop, A. Petit, “Molecular biology and genetics of Alzheimer’s disease”, Comptes Rendus Biologies, vol. 328, no. 2, pp. 119-130, 2004. M. Plečkaitytė, “Alzheimer’s disease: a molecular mechanism, new hypotheses, and therapeutic strategies”, Medicina, vol. 46, no. 1, 2010.
  7. P. H. St George-Hyslop. “Molecular Genetics of Alzheimer’s Disease”, Biol Psychiatry, vol. 47, no. 3, pp. 183-199, 2000.
  8. Y. Cai, S. S. An, S. Kim, “Mutations in presenilin 2 and its implications in Alzheimer’s disease and other dementiaassociated disorders”, Clin Interv Aging, vol. 10, pp. 1163-1172, 2015.
  9. G. D. Schellenberg, T. D. Bird, E. M. Wijsman, H. T. Orr, L. Anderson, E. Nemens, J. A. White, L. Bonnycastle, J. L. Weber, M. E. Alonso, H. Potter, L. L. Heston, G. M. Martin, “Genetic linkage evidence for a familial Alzheimer’s disease locus on chromosome 14”, Science, vol. 258, pp. 668-671, 1992.
  10. D. Campion, J. M. Flaman, A. Brice, D. Hannequin, C. Martin, V. Moreau, F. Charbonnier, O. Didierjean, S. Tardieu, C. Penet, M. Puel, F. Pasquier, F. Le Doze, G. Bellis, A. Calenda, R. Heilig, M. Martinez, J. Mallet, M. Bellis, F. C. Darpoux, Y. Agid, T. Frebourg, “Mutations of the presenilin I gene in families with early-onset Alzheimer’s disease”, Hum Mol Genet, vol. 4, no. 12, pp. 373- 377, 1995.
  11. R. F. Clark, M. Cruts, K. M. Korenblat, C. He, C. Talbot, C. Van Broeckhoven, A. M. Goate, “A yeast artificial chromosome contig from human chromosome 14q24 spanning the Alzheimer’s disease locus AD3”, Hum Mol Genet, vol. 4, no. 8, pp.